Alberto Sogari
YOU?
Author Swipe
View article: The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer Open
The combination of 5-fluorouracil and irinotecan (FOLFIRI) remains a standard-of-care treatment for metastatic colorectal cancer (mCRC), yet benefits only about half of patients. Using patient-derived xenografts (PDXs), we investigated the…
View article: Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features
Early-Onset Colorectal Cancers Exhibit Distinctive Placental-Like Features Open
The incidence of early-onset colorectal cancer (EO-CRC, diagnosed earlier than age 50) is rising worldwide. Despite distinctive clinicopathological features, whether EO-CRC represents a biologically distinct entity from standard-onset CRC …
View article: 82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer
82P Intratumoral presence of the genotoxic gut bacteria pks+ E. coli in very early onset colorectal cancer Open
View article: Mutational signatures of colorectal cancers according to distinct computational workflows
Mutational signatures of colorectal cancers according to distinct computational workflows Open
Tumor mutational signatures have gained prominence in cancer research, yet the lack of standardized methods hinders reproducibility and robustness. Leveraging colorectal cancer (CRC) as a model, we explored the influence of computational p…
View article: Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells Open
View article: A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells Open
Compelling evidence shows that cancer persister cells represent a major limit to the long-term efficacy of targeted therapies. However, the phenotype and population dynamics of cancer persister cells remain unclear. We developed a quantita…
View article: Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer Open
View article: Drug-induced colorectal cancer persister cells show increased mutation rate
Drug-induced colorectal cancer persister cells show increased mutation rate Open
Compelling evidence shows that cancer persister cells limit the efficacy of targeted therapies. However, it is unclear whether persister cells are induced by anticancer drugs, and if their mutation rate quantitatively increases during trea…
View article: Adaptive mutability of colorectal cancers in response to targeted therapies
Adaptive mutability of colorectal cancers in response to targeted therapies Open
A cross-kingdom tale of drug resistance Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics,…
View article: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies Open
Attempts at eradicating metastatic cancers with targeted therapies are limited by the emergence of resistant subclones bearing heterogeneous (epi)genetic changes. We used colorectal cancer (CRC) to test the hypothesis that interfering with…
View article: 2 Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
2 Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies Open
Introduction Clinical effectiveness of targeted therapies is often transitory and virtually all patients develop secondary resistance. The heterogeneous mechanisms of resistance and the sub-clonal evolution pattern of cell populations tha…